Alendronate Sodium
Product Images NDC 55695-012

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 55695-012). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Department Of State Health Services, Pharmacy Branch, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Label)

Pharmacy label for alendronate sodium tablets, 70 mg strength, provided by the City of Houston Pharmacy Commerce. The label instructs taking one tablet once weekly on an empty stomach with a full glass of water. The package contains 4 tablets. Expiration date on label is 06/30/2016.*

FDA Label Image

Alendronate-sodium-tablets-1 (Alendronate Sodium Tablets 1)

Packaging label for alendronate sodium tablets from the Department of State Health Services, Pharmacy Branch, showing a white round tablet. Visible text includes the product name alendronate sodium and some dosage and lot information on the back side of the blister packaging.*

FDA Label Image

Alendronate-sodium-tablets-10 (Alendronate Sodium Tablets 10)

Alendronate sodium 70 mg film-coated tablets carton from the Department of State Health Services, Pharmacy Branch. The front panel shows the proprietary name and strength, the dosage form as film-coated tablets, and the package contains 4 tablets. The labeling uses blue and white colors on the carton.*

FDA Label Image

Alendronate-sodium-tablets-11 (Alendronate Sodium Tablets 11)

Alendronate sodium tablet bottle label from the Department of State Health Services, Pharmacy Branch. The label includes product identification and contains details such as the product name and NDC 55695-012. The bottle is white with a white cap and a readable label displaying the medication name.*

FDA Label Image

Alendronate-sodium-tablets-2 (Alendronate Sodium Tablets 2)

Alendronate sodium tablet bottle label from the Department of State Health Services, Pharmacy Branch. The label includes the proprietary name alendronate sodium and displays standard pharmacy labeling elements on a white background with black and blue text.*

FDA Label Image

Alendronate-sodium-tablets-3 (Alendronate Sodium Tablets 3)

Chemical structure of alendronate sodium, showing its molecular configuration including phosphonate groups and associated sodium and water molecules.*

FDA Label Image

Alendronate-sodium-tablets-4 (Alendronate Sodium Tablets 4)

A line graph showing cumulative incidence (%) over time in months up to 36 months, comparing alendronate sodium versus placebo. The graph features two lines: one for placebo with higher cumulative incidence, and one for alendronate sodium with lower cumulative incidence, indicating data trends for these groups over the study period.*

FDA Label Image

Alendronate-sodium-tablets-5 (Alendronate Sodium Tablets 5)

A bar graph comparing percent increase in bone mineral density (BMD) at three anatomical sites — Lumbar Spine, Femoral Neck, and Trochanter — relative to placebo ± standard error (SE) between U.S. and multinational groups. The U.S. group shows higher BMD increase at all sites compared to the multinational group.*

FDA Label Image

Alendronate-sodium-tablets-6 (Alendronate Sodium Tablets 6)

Two line graphs depicting mean percent change from baseline in bone mineral density (BMD) over 36 months. The left graph is labeled 'U.S. Study' and the right 'Multinational Study.' Both compare Alendronate Sodium 10 mg (solid circles) and placebo (open circles), showing an increase in BMD for Alendronate Sodium and little to no change for placebo over time.*

FDA Label Image

Alendronate-sodium-tablets-7 (Alendronate Sodium Tablets 7)

Two bar graphs showing the change in bone mineral density (BMD) from baseline comparing alendronate sodium 5 mg/day to placebo in a 2-year study and a 3-year study. BMD changes are reported for lumbar spine, femoral neck, trochanter, and total body, with alendronate sodium generally showing positive change versus negative change for placebo.*

FDA Label Image

Alendronate-sodium-tablets-8 (Alendronate Sodium Tablets 8)

A bar graph comparing percent increase in bone mineral density (BMD) relative to placebo at three bone sites: lumbar spine, femoral neck, and trochanter. Two groups are shown: U.S. and Multinational, with error bars indicating standard error.*

FDA Label Image

Alendronate-sodium-tablets-9 (Alendronate Sodium Tablets 9)

A line graph showing the mean percent change from baseline in serum alkaline phosphatase over 6 months. The graph compares placebo, etidronate 400 mg/day, alendronate sodium 40 mg/day multinational study, and alendronate sodium 40 mg/day U.S. study groups with data points at 0, 3, and 6 months. Sample sizes (N) are indicated for each group at the 6-month mark.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.